Clinical Trial Update: Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED) [Phase 1]

View source ↗

Summary

This is a completed Phase 1 crossover trial evaluating whether donepezil and the investigational MK-3134 can reverse scopolamine-induced cognitive impairment in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia

Drugs mentioned

• Donepezil (donepezil)
• MK-3134 (MK-3134)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dementia | Phase 1 | Status: COMPLETED